Name | Value |
---|---|
Revenues | 204.5M |
Cost of Revenue | 100.1M |
Gross Profit | 104.4M |
Operating Expense | 151.9M |
Operating I/L | -47.5M |
Other Income/Expense | 0.1M |
Interest Income | 1.7M |
Pretax | -47.3M |
Income Tax Expense | 1.6M |
Net Income/Loss | -49.0M |
Tandem Diabetes Care, Inc. is a medical device company specializing in products for insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes the t:slim X2 pump, disposable insulin cartridge, and infusion set. The company also offers t:slim X2 with Basal-IQ and control IQ technology, t:slim X2 with G5 Integration, and the Tandem Device Updater. Additionally, it provides t:connect, a web-based data management application, and Sugarmate, a mobile app for insulin users. Tandem has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories, driving its revenue through the sale of these medical devices and related technologies.